Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

EP: 1.Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients

EP: 2.Upcoming Generics Provide New Considerations and Opportunities for Savings

EP: 3.Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

EP: 4.Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting

EP: 5.Dermatologists’ Focus to Delve Below the Skin at Annual Conference

EP: 6.Experts Herald “Year of the JAK Inhibitor” in Dermatology

EP: 7.Dr Monica Li Highlights Advances in Microneedling

EP: 8.Dr Eva Parker: Climate Change Has Been Impacting Skin Diseases for Years

EP: 9.Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

EP: 10.Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo

EP: 11.Late-Breaking Abstracts Demonstrate Value of Persistence With Ruxolitinib Cream for Vitiligo

EP: 12.Examining Dermatological Care for Transgender Patients

EP: 13.How Our Understanding of Inflammatory Skin Disease Has Evolved From the 4 Humors to Targeted Therapies

EP: 14.Dr Haley Naik Discusses Using Biologics and the Drug Pipeline for Hidradenitis Suppurativa

EP: 15.Drs Dellavalle and Rodriguez Discuss Disparities in Prescription Patterns for Atopic Dermatitis

EP: 16.Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability

EP: 17.Investigators Highlight Disparities Evident in Skin Disease Care, Data Collection

EP: 18.Studies Presented at AAD Examine Safety and Satisfaction of Tildrakizumab for Psoriasis

EP: 19.Patients With AD Have More Options With Biologics, JAK Inhibitors, Says Dr Emma Guttman-Yassky

EP: 20.Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says

EP: 21.Teledermatology Can Increase Access for Patients With High-Risk Melanoma: Erik Jaklitsch

EP: 22.Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early

EP: 23.Panel Discusses Treating Acne, Psoriasis in Dermatology Patients

EP: 24.New and Upcoming Treatment for Vitiligo, Atopic Dermatitis

EP: 25.Long-Term Safety of Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

EP: 26.Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment

EP: 27.ICYMI: Highlights From RAD 2023

EP: 28.AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics

EP: 29.Dr Amy Paller Previews the 2024 AAD Annual Conference

EP: 30.Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

EP: 31.Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

EP: 32.Atopic Dermatitis in Adults: Challenges and Treatment Strategies

EP: 33.Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

EP: 34.Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

EP: 35.Skin Tone Bias Persists in Google Searches for Vitiligo

EP: 36.Management of HS Requires Both Coordination, Communication Between Patients and Providers

EP: 37.Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

EP: 38.Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

EP: 39.Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

Now Viewing

EP: 40.Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

EP: 41.Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

EP: 42.New Study Links Social Factors to Hidradenitis Suppurativa Severity

EP: 43.Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

EP: 44.Dr Shawn Kwatra Shares Efficacy, Safety Data of Nemolizumab in Patients With PN

EP: 45.Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis

EP: 46.Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

EP: 47.Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

EP: 48.Autoimmune Comorbidities Prevalent in Patients With Vitiligo

EP: 49.Skin Cancer Incidence Highest Among Rural, SOC Individuals

EP: 50.Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

EP: 51.Gaps in Skincare Knowledge, Sun Protection Practice Exist Among Patients With Lupus

EP: 52.Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD

EP: 53.Undertreatment, Biologic Access Gaps Identified in Psoriasis Treatment

EP: 54.Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment

EP: 55.Dr Monica Li Lists Microneedling Considerations, Precautions

EP: 56.Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults

EP: 57.Dr Lawrence Eichenfield Discusses Positive Results of Roflumilast Cream 0.05% in Pediatric Patients With AD

EP: 58.Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice

EP: 59.Dr Monica Li Explains Efficacy, Safety Differences Between Different Microneedling Techniques

EP: 60.Dr Lawrence Eichenfield Hopeful for New Pediatric AD Treatment Option

EP: 61.Dr Martina Porter Shares Findings on Ruxolitinib Cream in Patients With HS

EP: 62.Dr Martin Dahl Summarizes Findings, Limitations of Study Analyzing ANB032 Use in Patients With AD

This content was produced independently by The American Journal of Managed Care^® and is not endorsed by the American Academy of Dermatology.

Acute pain is a significant factor for patients with hidradenitis suppurativa (HS) that can be reduced by treating the inflammation associated with this disease, says Jeff Stark, MD, vice president, head of medical immunology, UCB.

Transcript

What specific improvements in skin pain were observed in patients with hidradenitis suppurative (HS) treated with bimuzkizumab-bkzx compared with placebo?

We're very excited about the skin pain results that we're presenting here for bimekizumab at the AAD meeting [American Academy of Dermatology Annual Meeting 2024]. Bimekizumab, as you may know or your listeners may know, is a novel molecule that targets 2 different components of the IL [interleukin]-17 pathway, both IL-17A and IL-17F, both of which we know are potent drivers of inflammation in inflammatory skin diseases like Hidradenitis suppurativa.

We've previously presented our pain results in HS, but are now looking at longer-term data, specifically from week 16 onto week 48. We saw rapid reductions in pain previously in that week 16 segment of the data, which was the placebo-controlled data. Now we're looking at more long-term open label extension data and are very pleased to see that we are observing continued improvements in pain that follow on to that rapid reduction over 16 weeks. Those patients who continue to bimekizumab or who switch to bimekizumab from placebo at week 16 continue to experience longer-term reductions in pain as well.

The reason I think this is exciting is really 2 reasons. One is that these are longer-term data that helps us to know what to expect as patients are treated with bimekizumab over longer periods of time. Also, because pain is among the most prominent symptoms that patients with HS experience, and so, to be able to speak to their experience with the disease and demonstrate effectiveness of a therapy to reduce that prominent symptom for them is particularly exciting as well.